Buparlisib: Difference between revisions

From WikiMD's Wellness Encyclopedia

← Older edit
CSV import
CSV import
 
Line 1: Line 1:
'''Buparlisib''' (BKM120) is a highly specific oral inhibitor of the phosphatidylinositol-3-kinase (PI3K) family, a group of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking, which are integral to the development and progression of cancers. Buparlisib has shown potential in targeting the PI3K pathway in cancer cells, making it a subject of interest in oncology research for its therapeutic potential in various cancers.
== Buparlisib ==


==Mechanism of Action==
[[File:Buparlisib.svg|thumb|right|Chemical structure of Buparlisib]]
Buparlisib inhibits the activity of the PI3K enzymes by binding to the ATP-binding cleft of these enzymes. This inhibition prevents the activation of the PI3K/AKT/mTOR pathway, a signaling pathway that is often overactive in many types of cancer cells, leading to uncontrolled cell growth and survival. By targeting this pathway, buparlisib aims to reduce tumor growth and proliferation.


==Clinical Trials==
'''Buparlisib''' is an investigational drug that acts as a pan-class I [[phosphoinositide 3-kinase]] (PI3K) inhibitor. It is primarily being studied for its potential use in the treatment of various types of [[cancer]].
Clinical trials have been conducted to evaluate the efficacy and safety of buparlisib in various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and glioblastoma. These studies have explored buparlisib as both a monotherapy and in combination with other cancer therapies. While some trials have shown promise, the results have been mixed, with challenges such as toxicity and the development of resistance limiting its effectiveness in some cases.


==Adverse Effects==
== Mechanism of Action ==
The most common adverse effects associated with buparlisib include hyperglycemia, nausea, rash, fatigue, and mood changes. These side effects are generally manageable but have led to dose reductions or discontinuation in some patients. The risk of serious adverse events underscores the importance of careful patient monitoring during treatment with buparlisib.


==Current Status==
Buparlisib works by inhibiting the activity of the PI3K enzyme, which is part of the [[PI3K/AKT/mTOR pathway]]. This pathway is crucial for regulating cell growth, proliferation, and survival. In many cancers, this pathway is dysregulated, leading to uncontrolled cell growth and survival. By inhibiting PI3K, buparlisib aims to restore normal cell cycle control and induce [[apoptosis]] in cancer cells.
As of the last update, buparlisib is not yet approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of any cancer. Research and development efforts continue, with ongoing clinical trials aiming to better understand its therapeutic potential and to identify patient populations that may benefit most from this treatment.


==Future Directions==
== Clinical Development ==
Future research on buparlisib includes further clinical trials to optimize its use, including combination therapy strategies, dose optimization, and the identification of biomarkers to predict response to therapy. The development of strategies to manage or prevent resistance to buparlisib is also a critical area of focus.


==See Also==
Buparlisib has been evaluated in several clinical trials for its efficacy and safety in treating different types of cancer, including [[breast cancer]], [[lung cancer]], and [[glioblastoma]]. It is often studied in combination with other therapies to enhance its anticancer effects.
* [[Phosphatidylinositol 3-kinase]]
 
* [[Oncology]]
=== Breast Cancer ===
 
In breast cancer, particularly in hormone receptor-positive, HER2-negative subtypes, buparlisib has been investigated in combination with [[endocrine therapy]]. The rationale is to overcome resistance to endocrine therapy by targeting the PI3K pathway.
 
=== Glioblastoma ===
 
Glioblastoma, a highly aggressive form of brain cancer, has also been a target for buparlisib studies. The drug's ability to cross the [[blood-brain barrier]] makes it a candidate for treating brain tumors.
 
== Side Effects ==
 
Common side effects of buparlisib include [[hyperglycemia]], [[rash]], and [[diarrhea]]. Due to its mechanism of action, it can also affect normal cells, leading to adverse effects such as [[fatigue]] and [[nausea]].
 
== Related Pages ==
 
* [[Phosphoinositide 3-kinase]]
* [[PI3K/AKT/mTOR pathway]]
* [[Cancer treatment]]
* [[Clinical trial]]
* [[Clinical trial]]
* [[Adverse effect]]
* [[Breast cancer]]
* [[Non-small cell lung cancer]]
* [[Glioblastoma]]


[[Category:Cancer treatment]]
[[Category:Experimental cancer drugs]]
[[Category:Experimental drugs]]
[[Category:Phosphoinositide 3-kinase inhibitors]]
{{Chemotherapy}}
{{medicine-stub}}
{{No image}}

Latest revision as of 04:00, 13 February 2025

Buparlisib[edit]

Chemical structure of Buparlisib

Buparlisib is an investigational drug that acts as a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. It is primarily being studied for its potential use in the treatment of various types of cancer.

Mechanism of Action[edit]

Buparlisib works by inhibiting the activity of the PI3K enzyme, which is part of the PI3K/AKT/mTOR pathway. This pathway is crucial for regulating cell growth, proliferation, and survival. In many cancers, this pathway is dysregulated, leading to uncontrolled cell growth and survival. By inhibiting PI3K, buparlisib aims to restore normal cell cycle control and induce apoptosis in cancer cells.

Clinical Development[edit]

Buparlisib has been evaluated in several clinical trials for its efficacy and safety in treating different types of cancer, including breast cancer, lung cancer, and glioblastoma. It is often studied in combination with other therapies to enhance its anticancer effects.

Breast Cancer[edit]

In breast cancer, particularly in hormone receptor-positive, HER2-negative subtypes, buparlisib has been investigated in combination with endocrine therapy. The rationale is to overcome resistance to endocrine therapy by targeting the PI3K pathway.

Glioblastoma[edit]

Glioblastoma, a highly aggressive form of brain cancer, has also been a target for buparlisib studies. The drug's ability to cross the blood-brain barrier makes it a candidate for treating brain tumors.

Side Effects[edit]

Common side effects of buparlisib include hyperglycemia, rash, and diarrhea. Due to its mechanism of action, it can also affect normal cells, leading to adverse effects such as fatigue and nausea.

Related Pages[edit]

Retrieved from "https://wikimd.com/index.php?title=Buparlisib&oldid=6292286"